Brief: Bellicum Pharmaceuticals qtrly loss per share $0.74
08/08/2017 21:05
Aug 8 (Reuters) - Bellicum Pharmaceuticals Inc BLCM.O
* Bellicum pharmaceuticals reports second quarter 2017
financial results and provides corporate update
* Bellicum pharmaceuticals inc qtrly loss per share $0.74
* Bellicum pharmaceuticals inc says enrollment in pivotal eu
bp-004 trial remains on track for completion by end of 2017
* Bellicum pharmaceuticals -expects to initiate
observational trial in pediatric patients receiving transplants
from matched unrelated donors without bpx-501 in q3
Source text for Eikon: ID:nGNXOCXWJa
Further company coverage: BLCM.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Bellicum Pharmaceuticals
See all newsBrief: Bellicum Pharmaceuticals- In Connection With Dissolution And Plan Of Dissolution, On February 23, Richard A. Fair Resigned As President And Co's CEO
Brief: Bellicum Pharmaceuticals Says Board Approved Liquidation And Dissolution Of Co In Connection With Approval Of Asset Purchase Agreement
Brief: Bellicum Pharmaceuticals Initiated A 12 Stock Split On Dec 8, 2022
Brief: Bellicum Reports Third Quarter 2022 Financial Results And Provides Operational Update
Bellicum Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview